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Background: Exposed phosphatidylserine (PS) in the tumor microenvironment is highly 
immunosuppressive. Bavituximab targets PS in the presence of β2GP1 as a high affinity complex and 
repolarizes myeloid derived suppressor cells and M2 macrophages to M1, resulting in production of pro-
inflammatory cytokines such as IFNγ and IL-12, maturation of dendritic cells and induction of tumor 
specific cytotoxic T lymphocyte immunity. In a prior double-blind Phase II trial in 2nd line non-squamous 
NSCLC, bavituximab 3 mg/kg plus docetaxel was well-tolerated and demonstrated 60% improvement 
(11.7 vs 7.3 month) in median overall survival (OS) compared to control. 
Methods: We accrued 597 patients with Stage IIIb/IV non-squamous NSCLC who progressed on 
platinum-doublet chemotherapy in a 1:1 ratio to receive up to six 21-day cycles... 
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